{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:11:50Z","timestamp":1760551910285},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The majority of corticotroph adenomas are benign but some are locally invasive, demonstrate high rates of recurrence, and exhibit a relatively poor response to often repeated surgical, medical, and radiation treatment. Herein, we summarize the currently known somatic and genetic mutations and other molecular factors that influence the pathogenesis of these tumors and discuss currently available therapies. Although recent molecular studies have advanced our understanding of the pathogenesis and behavior of these refractory corticotroph adenomas, these insights do not reliably guide treatment choices at present. Development of additional diagnostic tools and novel tumor-directed therapies that offer efficacious treatment choices for patients with refractory corticotroph adenomas are needed.<\/jats:p>","DOI":"10.1007\/s11102-023-01308-5","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:05:18Z","timestamp":1679871918000},"page":"269-272","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Refractory corticotroph adenomas"],"prefix":"10.1007","volume":"26","author":[{"given":"Amit K. S.","family":"Sumal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony P.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"8","key":"1308_CR1","doi-asserted-by":"publisher","first-page":"e13169","DOI":"10.1111\/jne.13169","volume":"34","author":"H Lasolle","year":"2022","unstructured":"Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G (2022) Aggressive corticotroph tumors and carcinomas. J Neuroendocrinol 34(8):e13169. https:\/\/doi.org\/10.1111\/jne.13169","journal-title":"J Neuroendocrinol"},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"650791","DOI":"10.3389\/fendo.2021.650791","volume":"12","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Nakao T, Ogawa W, Fukuoka H (2021) Aggressive Cushing\u2019s Disease: Molecular Pathology and its therapeutic Approach. Front Endocrinol (Lausanne) 12:650791 Published 2021 Jun 16. https:\/\/doi.org\/10.3389\/fendo.2021.650791","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1308_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11102-022-01253-9","volume":"25","author":"M Theodoropoulou","year":"2022","unstructured":"Theodoropoulou M, Reincke M (2022) Genetics of Cushing\u2019s disease: from the lab to clinical practice. Pituitary 25(5):689\u2013692. https:\/\/doi.org\/10.1007\/s11102-022-01253-9","journal-title":"Pituitary"},{"issue":"7","key":"1308_CR4","doi-asserted-by":"publisher","first-page":"E997","DOI":"10.1210\/jc.2015-1453","volume":"100","author":"LG Perez-Rivas","year":"2015","unstructured":"Perez-Rivas LG, Theodoropoulou M, Ferra\u00f9 F et al (2015) The gene of the ubiquitin-specific protease 8 is frequently mutated in Adenomas causing Cushing\u2019s Disease. J Clin Endocrinol Metab 100(7):E997\u2013E1004. https:\/\/doi.org\/10.1210\/jc.2015-1453","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1308_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"ZY Ma","year":"2015","unstructured":"Ma ZY, Song ZJ, Chen JH et al (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25(3):306\u2013317. https:\/\/doi.org\/10.1038\/cr.2015.20","journal-title":"Cell Res"},{"issue":"1","key":"1308_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47(1):31\u201338. https:\/\/doi.org\/10.1038\/ng.3166","journal-title":"Nat Genet"},{"issue":"3","key":"1308_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","volume":"106","author":"AV Uzilov","year":"2021","unstructured":"Uzilov AV, Taik P, Cheesman KC et al (2021) USP8 and TP53 drivers are Associated with CNV in a Corticotroph Adenoma Cohort enriched for aggressive tumors. J Clin Endocrinol Metab 106(3):826\u2013842. https:\/\/doi.org\/10.1210\/clinem\/dgaa853","journal-title":"J Clin Endocrinol Metab"},{"key":"1308_CR8","doi-asserted-by":"publisher","unstructured":"Chen J, Jian X, Deng S et al (2018) Identification of recurrent USP48 and BRAF mutations in Cushing\u2019s disease. Nat Commun. ;9(1):3171. Published 2018 Aug 9. doi:https:\/\/doi.org\/10.1038\/s41467-018-05275-5","DOI":"10.1038\/s41467-018-05275-5"},{"issue":"1","key":"1308_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1677\/ERC-08-0167","volume":"16","author":"Y Lin","year":"2009","unstructured":"Lin Y, Jiang X, Shen Y et al (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 16(1):301\u2013310. https:\/\/doi.org\/10.1677\/ERC-08-0167","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1308_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstr\u00f6m BE et al (2021) Corticotroph Aggressive Pituitary Tumors and Carcinomas frequently Harbor ATRX mutations. J Clin Endocrinol Metab 106(4):1183\u20131194. https:\/\/doi.org\/10.1210\/clinem\/dgaa749","journal-title":"J Clin Endocrinol Metab"},{"key":"1308_CR11","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez de LaPiscina I, Hern\u00e1ndez-Ram\u00edrez LC, Portillo N et al (2020) Rare Germline DICER1 Variants in Pediatric Patients With Cushing\u2019s Disease: What Is Their Role?. Front Endocrinol (Lausanne). ;11:433. Published 2020 Jul 3. doi:https:\/\/doi.org\/10.3389\/fendo.2020.00433","DOI":"10.3389\/fendo.2020.00433"},{"issue":"8","key":"1308_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1530\/ERC-17-0131","volume":"24","author":"LC Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez LC, Gam R, Vald\u00e9s N et al (2017) Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing\u2019s disease. Endocr Relat Cancer 24(8):379\u2013392. https:\/\/doi.org\/10.1530\/ERC-17-0131","journal-title":"Endocr Relat Cancer"},{"key":"1308_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000147748","volume":"154","author":"E Hay","year":"1995","unstructured":"Hay E (1995) An overview of epithelio-mesenchymal transformation. Acta Anat 154:8\u201320. https:\/\/doi.org\/10.1159\/000147748","journal-title":"Acta Anat"},{"issue":"6","key":"1308_CR14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/jci39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420\u20131428. https:\/\/doi.org\/10.1172\/jci39104","journal-title":"J Clin Invest"},{"key":"1308_CR15","doi-asserted-by":"publisher","unstructured":"Gil J, Jord\u00e0 M, Soldevila B, Puig-Domingo M (2021) Epithelial\u2013mesenchymal transition in the resistance to somatostatin receptor ligands in Acromegaly. Front Endocrinol 12. https:\/\/doi.org\/10.3389\/fendo.2021.646210","DOI":"10.3389\/fendo.2021.646210"},{"issue":"1","key":"1308_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson M-L, Septier A et al (2020) Pangenomic classification of Pituitary neuroendocrine tumors. Cancer Cell 37(1):123\u201334e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002","journal-title":"Cancer Cell"},{"issue":"1","key":"1308_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1530\/EJE-21-1183","volume":"187","author":"D Zhang","year":"2022","unstructured":"Zhang D, Hugo W, Bergsneider M et al (2022) Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior. Eur J Endocrinol 187(1):49\u201364 Published 2022 May 12. https:\/\/doi.org\/10.1530\/EJE-21-1183","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1308_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","volume":"23","author":"A Stroud","year":"2020","unstructured":"Stroud A, Dhaliwal P, Alvarado R et al (2020) Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis. Pituitary 23(5):595\u2013609. https:\/\/doi.org\/10.1007\/s11102-020-01066-8","journal-title":"Pituitary"},{"issue":"5","key":"1308_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17446651.2020.1802243","volume":"15","author":"C Capatina","year":"2020","unstructured":"Capatina C, Hinojosa-Amaya JM, Poiana C, Fleseriu M (2020) Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15(5):321\u2013339. https:\/\/doi.org\/10.1080\/17446651.2020.1802243","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1308_CR20","doi-asserted-by":"publisher","first-page":"106151","DOI":"10.1016\/j.clineuro.2020.106151","volume":"197","author":"M Kara","year":"2020","unstructured":"Kara M, G\u00fcd\u00fck M, Samanci Y, Yilmaz M, \u015eeng\u00f6z M, Peker S (2020) Gamma knife radiosurgery in patients with Cushing\u2019s disease: comparison of aggressive pituitary corticotroph tumor versus corticotroph adenoma. Clin Neurol Neurosurg 197:106151. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106151","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"1308_CR21","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G et al (2021) Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184(3):P1\u2013P16. https:\/\/doi.org\/10.1530\/EJE-20-1088","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1308_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933","journal-title":"Eur J Endocrinol"},{"key":"1308_CR23","doi-asserted-by":"publisher","unstructured":"Ilie MD, Lasolle H, Raverot G (2019) Emerging and Novel Treatments for Pituitary Tumors. J Clin Med. ;8(8):1107. Published 2019 Jul 25. doi:https:\/\/doi.org\/10.3390\/jcm8081107","DOI":"10.3390\/jcm8081107"},{"issue":"3","key":"1308_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/a-1260-3975","volume":"129","author":"K Osterhage","year":"2021","unstructured":"Osterhage K, Rotermund R, Droste M et al (2021) Bevacizumab in Aggressive Pituitary Adenomas - experience with 3 patients. Exp Clin Endocrinol Diabetes 129(3):178\u2013185. https:\/\/doi.org\/10.1055\/a-1260-3975","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"1308_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","volume":"30","author":"OM Alshaikh","year":"2019","unstructured":"Alshaikh OM, Asa SL, Mete O, Ezzat S (2019) An institutional experience of Tumor Progression to Pituitary Carcinoma in a 15-Year cohort of 1055 consecutive pituitary neuroendocrine tumors. Endocr Pathol 30(2):118\u2013127. https:\/\/doi.org\/10.1007\/s12022-019-9568-5","journal-title":"Endocr Pathol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01308-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:24:02Z","timestamp":1688981042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01308-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"4 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors do not have any conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}